Anaplastic Astrocytoma - A Pipeline Analysis Report

Overview of the drug development pipeline for anaplastic astrocytoma

Anaplastic astrocytoma is a malignant brain tumor, which is caused by astrocytoma. Astrocytoma is mostly associated with certain hereditary issues including tuberous sclerosis, neurofibromatosis type I, and the LI-Fraumeni syndrome. People suffering from this tumor experience various symptoms including seizures, depression, focal neurological deficit, and headache. Technavio’s market research analysts have predicted that anaplastic astrocytoma market growth will be witnessed with the introduction of radiation therapy (RT) and chemotherapy as some of the most promising approaches to treat anaplastic astrocytoma, the global anaplastic astrocytoma market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase I development stage. For instance, sponsors such as Amgen developed AMG 595 and Boehringer Ingelheim developed Afatinib, which are under phase I stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the pre-clinical, phase III, and phase II/III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the phase II stage.

Anaplastic astrocytoma industry analysis: Companies covered

According to the anaplastic astrocytoma industry analysis, this report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of anaplastic astrocytoma. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Amgen
• AngioChem
• Northwell Health

Therapeutic assessment of the drug development pipeline for anaplastic astrocytoma by the preferred route of administration

• Oral
• IV
• Intra-arterially
• Oral + IV

The oral route of administration (ROA) involves the administration of drug substances through a mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for anaplastic astrocytoma by types of molecules used

• Small molecule
• Biomolecule
• Monoclonal
• Vaccine

According to anaplastic astrocytoma industry insights, the majority of molecules that are currently in the drug development pipeline for anaplastic astrocytoma are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for anaplastic astrocytoma?
• What are the companies that are currently involved in the development of drug development molecules for anaplastic astrocytoma?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.